MetaCap

TransMedics Group Inc. (TMDX)

NASDAQ: TMDXHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD

85.25-8.77 (-9.33%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TMDX stock chart

Technical analysis

Key statistics

All statistics
52-week range
60.11 – 156.00
Day range
83.89 – 91.62
Volume / Avg
1.59M / 930.13K
Beta
—

52-week range

$60.11$156.00

TMDX stock today

TransMedics Group (TMDX) closed at $85.25 on Nov 20, down 9.33% (-$8.77), versus the S&P 500's 3.70% decline. Shares are 45.4% below their 52-week high of $156.00, set on Dec 2, 2025 and 41.8% above the 52-week low of $60.11, in the middle of the past year's range. TMDX is down 29.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 34.9%.

At 23.2x trailing earnings, TransMedics Group trades above the peer-group median of 18.0x. Its forward P/E of 34.3x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About TransMedics Group

Company profile

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers.

Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
CEO
Dr. Waleed H. Hassanein M.D.
Headquarters
Andover, MA
Employees
898
IPO year
2019

Financial highlights

Full financials

In fiscal 2025, TransMedics Group generated $605.5 million in revenue, up 37.1% from fiscal 2024, its 7th consecutive year of revenue growth. Net income was $190.3 million (+436.6% year over year), for a net margin of 31.4% versus a median of -38.8% in the prior 5 years. Gross margin was 59.9% (up from 59.4%) and operating margin 17.9%.

TransMedics Group annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$605.49M$441.54M$241.62M$93.46M$30.26M
Growth+37.13%+82.74%+158.53%+208.83%+18.03%
Net income$190.29M$35.46M$-25.03M$-36.23M$-44.22M
EPS (diluted)$4.87$1.01$-0.77$-1.23$-1.60

Analyst forecast

Forecast

Consensus (13 analysts)

buy

Avg. price target

$105.45+23.70%

  • Strong buy 3
  • Buy 6
  • Hold 4
  • Sell 0
  • Strong sell 0

Target range

Low $80.00High $125.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$0.66 vs $0.27
Surprise
+144.44%

TMDX news

All TMDX news

TransMedics Group peers

Health Care sector
TMDX peer companies
CompanyPrice% ChgMarket capCompare
AXGNAxogen Inc.55.75-1.06%$3.33Bvs TMDX
CNMDCONMED Corporation46.56+0.39%$1.39Bvs TMDX
CBLLCeriBell Inc.27.39+6.37%$1.06Bvs TMDX
LIVNLivaNova PLC90.73-1.46%$5.00Bvs TMDX
INMDInMode Ltd.12.42-2.20%$714.70Mvs TMDX
CVCapsoVision Inc.6.11-3.17%$327.56Mvs TMDX
ELMDElectromed Inc.22.98-1.20%$187.84Mvs TMDX
FOCLEDAP TMS S.A. ADR2.61-7.45%$123.25Mvs TMDX

Indexes, lists and sector

TransMedics Group stock FAQ

What is TransMedics Group's stock price today?

TMDX last traded at $85.25 as of Nov 20, 4:00 PM EST, down 9.33% on the day. Prices are delayed at least 15 minutes.

What is TMDX's P/E ratio?

TMDX trades at a trailing P/E ratio of 23.23 and a forward P/E of 34.31, compared with a median of 18.0 for its closest peers.

Who is TransMedics Group's CEO?

Dr. Waleed H. Hassanein M.D. is the chief executive officer of TransMedics Group Inc., which has about 898 employees.

What is the TMDX 52-week high?

The 52-week high for TMDX is $156.00 and the 52-week low is $60.11. The stock is currently 45.4% below its high.

Compare TMDX